India’s first new discovery antibiotics from Wockhardt Granted Indian regulatory approval

Wockhardt: 1st Indian company to achieve approval for new discovered antibiotics

Wockhardt, DCGI, EMROK, EMROK O, Bacterial skin, Skin structure Infections, MRSA, AMR, Antimicrobial resistance, EMROK, EMROK-O, Habil Khorakiwala, Wockhardt Group, Indian Antibiotic market

Indian drug regulator, DCGI has approved Wockhardt’s two new antibiotics, EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India. The new drug will target superbug like Methicillin resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).

The size of Indian Antibiotic market is approx. 16,000 Crore, growing at 7% and is one of the largest therapeutic segment, with a 12% market share of the Indian Pharmaceutical Market1.

“By virtue of its broad spectrum activity against widely prevalent pathogens including MRSA, superior safety over the currently available anti-MRSA agents and its unique properties, I believe EMROK/EMROK-O has a strong potential to effectively address the unmet medical need of the clinicians in the country thereby helping to reduce the morbidity and mortality”- said Dr. Habil Khorakiwala, Founder Chairman, Wockhardt Group.